Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors. However, the specific role of EpCAM itself in ...
CytomX reports promising Phase 1 data for CX-2051 in advanced colorectal cancer, with planned Phase 2 study in 2026. CytomX Therapeutics announced positive interim results from its Phase 1 study of CX ...
CytomX is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer ...
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results